INVESTORS
Leading the future of self-care
Maxwellia is a fast-growing, female-founded consumer healthcare company revolutionising access to medicines. We convert prescription-only drugs into consumer friendly over-the-counter (OTC) brands, and we do it quickly and efficiently using our proven DynamicSwitch™ process. We’re empowering consumers to take control of their health while driving transformative growth in the £288bn global OTC market.
Backed by prominent investors, including Praetura Ventures, Channel 4 Ventures and the British Business Bank, along with the highly successful private investor, John Gunn, Maxwellia is uniquely positioned to lead the next wave of consumer healthcare innovation.
Current funding round
After successfully securing £1.5m from existing institutional investors, we are now seeking to raise an additional £2m to bring our total funding to £3.5m. This funding will support the next phase of our growth, including the expansion of our product pipeline, scaling our commercial operations, and advancing our international strategy.
WHY INVEST?
-
Track record of success: Four women’s health brands launched (two in the past three months), already achieving ARR of £2.2m and on track to achieve £3.1m revenue in 2025
-
Explosive growth trajectory: Qualified pipeline of products that will generate substantial revenue growth in excess of £22m by 2028, achieving EBITDA returns of 16%.
-
Enviable distribution: A strong national footprint across major retailers including Boots, Superdrug, Tesco, Asda, and Day Lewis, and significant opportunity for international expansion
-
Exceptional team: Led by pharmacist and self-care visionary Anna Maxwell, supported by an internationally recognised team at Alderley Park Life Sciences Hub
-
EIS pre-qualified: You can benefit from the Enterprise Investment Scheme offering a range of benefits to investors, including tax relief.
Sign up to our investor wait list below to learn more about this exclusive investment opportunity.
Always read the label
ABOUT YOUR EIS INVESTMENT
Don’t invest unless you’re prepared to lose all the money you invest. This is a high-risk investment.
Your investment in Maxwellia can benefit from the Enterprise Investment Scheme (EIS). EIS offers a range of benefits to investors:
Maxwellia is a Knowledge-Intensive Company
1. Income Tax Relief
Investors can claim up to 30% relief on investments in EIS-qualifying shares, up to £1 million annually (£2 million for Knowledge-Intensive Companies). The investment must be held for at least 3 years, and investors can "carry back" the relief to the previous tax year.
2. Capital Gains Tax (CGT) Freedom
No CGT is payable on shares sold after 3 years if income tax relief was received
and not withdrawn.
3. CGT Deferral Relief
Investors can defer CGT on gains from other assets by investing in EIS shares. The deferral lasts as long as the EIS shares are held.
4. Loss Relief
If shares are sold at a loss, the loss can be offset against capital gains or income, reducing the investment risk.
5. Business Relief for Inheritance Tax (IHT)
EIS shares may qualify for 100% IHT relief after 2 years, potentially eliminating inheritance tax on the investment.